Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy.
Irene Pachón-AngonaBernard RefouveletRudolf AndrýsHelène MartinVincent LuzetIsabel IriepaIgnacio MoraledaDaniel Diez-IriepaMaría-Jesús Oset-GasqueJosé Marco-ContellesKamil MusilekLhassane IsmailiPublished in: Journal of enzyme inhibition and medicinal chemistry (2019)
We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
Keyphrases
- small molecule
- end stage renal disease
- newly diagnosed
- cognitive decline
- ejection fraction
- chronic kidney disease
- oxidative stress
- peritoneal dialysis
- photodynamic therapy
- high intensity
- emergency department
- protein protein
- anti inflammatory
- risk assessment
- mesenchymal stem cells
- drug induced
- case control
- cell therapy
- smoking cessation